U.S. Markets open in 46 mins

Wall Street Analysts Are Mostly Positive on Merck in September

Daniel Collins
Wall Street Analysts Are Mostly Positive on Merck in September

Merck (MRK) recently announced that its pivotal Phase 3 trial that evaluated Zerbaxa met its primary endpoint. Zerbaxa is an investigational antibiotic for the treatment of adult individuals with ventilated hospital-acquired bacteria pneumonia or ventilator-associated bacterial pneumonia (or VABP). Zerbaxa demonstrated non-inferiority compared to meropenem.